NO20054133L - Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor - Google Patents

Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor

Info

Publication number
NO20054133L
NO20054133L NO20054133A NO20054133A NO20054133L NO 20054133 L NO20054133 L NO 20054133L NO 20054133 A NO20054133 A NO 20054133A NO 20054133 A NO20054133 A NO 20054133A NO 20054133 L NO20054133 L NO 20054133L
Authority
NO
Norway
Prior art keywords
aromatase inhibitor
rapamycin derivative
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
NO20054133A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054133D0 (no
Inventor
Jr James Joseph Gibbons
Matthew L Sherman
Mark Berger
Robert T Maguire
Robert Friedman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054133(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054133D0 publication Critical patent/NO20054133D0/no
Publication of NO20054133L publication Critical patent/NO20054133L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20054133A 2003-03-05 2005-09-06 Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor NO20054133L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45228903P 2003-03-05 2003-03-05
PCT/US2004/006354 WO2004078133A2 (en) 2003-03-05 2004-03-01 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor

Publications (2)

Publication Number Publication Date
NO20054133D0 NO20054133D0 (no) 2005-09-06
NO20054133L true NO20054133L (no) 2005-10-03

Family

ID=32962706

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054133A NO20054133L (no) 2003-03-05 2005-09-06 Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor

Country Status (20)

Country Link
US (1) US20040176339A1 (enExample)
EP (1) EP1603561A2 (enExample)
JP (1) JP2006519862A (enExample)
KR (1) KR20050109965A (enExample)
CN (1) CN1756549A (enExample)
AR (1) AR043403A1 (enExample)
AU (1) AU2004218439A1 (enExample)
BR (1) BRPI0408024A (enExample)
CA (1) CA2516353A1 (enExample)
CR (1) CR7942A (enExample)
EC (1) ECSP056001A (enExample)
MX (1) MXPA05009246A (enExample)
NI (1) NI200500148A (enExample)
NO (1) NO20054133L (enExample)
NZ (1) NZ542738A (enExample)
RU (1) RU2355399C2 (enExample)
TW (1) TW200529829A (enExample)
UA (1) UA83484C2 (enExample)
WO (1) WO2004078133A2 (enExample)
ZA (1) ZA200508029B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
KR20060052880A (ko) * 2003-07-25 2006-05-19 와이어쓰 동결건조된 ｃｃｉ- 779 제형
RU2006122517A (ru) * 2004-01-08 2008-02-20 Вайет (Us) Фармацевтический состав для прямого прессования, предназначенный для перорального введения cci-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
AU2005302004A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma
RU2405566C9 (ru) * 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
PE20070763A1 (es) * 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
AU2006314444C1 (en) * 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN102209539B (zh) * 2008-11-11 2013-06-12 伊莱利利公司 P70 s6激酶抑制剂和mtor抑制剂的组合治疗剂
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
EP2416792A4 (en) * 2009-04-10 2012-10-24 Haiyan Qi NOVEL ANTI-AGING AGENTS AND METHODS OF IDENTIFICATION
EP2648721B1 (de) * 2011-01-31 2018-09-19 LUCOLAS-M.D. Ltd. Kombinationen von aromatase inhibitoren und antioxidanzien
US9682066B2 (en) * 2012-12-04 2017-06-20 University Of Cincinnati Methods of treating primary brain tumors by administering letrozole
WO2015014284A1 (zh) * 2013-07-31 2015-02-05 北京盛诺基医药科技有限公司 一种乳腺癌的治疗方法
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
CN100448487C (zh) * 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PT2269603E (pt) * 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
PL363991A1 (en) * 2001-04-06 2004-11-29 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
UA78706C2 (en) * 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
BR0210101A (pt) * 2001-06-01 2004-06-08 Wyeth Corp Combinações antineoplásticas
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
CR7942A (es) 2006-02-07
AU2004218439A1 (en) 2004-09-16
AR043403A1 (es) 2005-07-27
NI200500148A (es) 2006-03-30
NZ542738A (en) 2009-02-28
UA83484C2 (uk) 2008-07-25
TW200529829A (en) 2005-09-16
EP1603561A2 (en) 2005-12-14
ZA200508029B (en) 2007-04-25
RU2355399C2 (ru) 2009-05-20
NO20054133D0 (no) 2005-09-06
CN1756549A (zh) 2006-04-05
BRPI0408024A (pt) 2006-02-14
JP2006519862A (ja) 2006-08-31
RU2005130767A (ru) 2006-02-10
US20040176339A1 (en) 2004-09-09
WO2004078133A3 (en) 2004-11-11
MXPA05009246A (es) 2005-10-19
ECSP056001A (es) 2006-01-27
WO2004078133A2 (en) 2004-09-16
CA2516353A1 (en) 2004-09-16
WO2004078133A8 (en) 2005-09-01
KR20050109965A (ko) 2005-11-22

Similar Documents

Publication Publication Date Title
NO20054133L (no) Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor
NO20054369D0 (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
DE60229922D1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
DE60228699D1 (de) Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
DE602004031670D1 (de) Stabilisierende plasma- und generatorinteraktionen
IS2914B (is) Kínólín afleiður og notkun þeirra sem tálma sveppagerla
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
IS7427A (is) 3-sýklýl-5-(5-hluta hringur sem inniheldur köfnunarefni) metýl-oxasólídínónafleiður og notkun þeirra sem bakteríueyðandi efna
NO20064130L (no) Antineoplastiske kombinasjoner av CCI-779 og rituximab
EP1653970A4 (en) GSK-3 HEMMER AND ITS USES
CY1105892T1 (el) Θepαπεια του ξανθωματος με παραγωγα αζετιδινονης ως αναστολεις απορροφησης στepολης
NL1025873A1 (nl) Doseringsvormen en wijzen van behandeling met vegfr-remmers.
SG136149A1 (en) Plasma source coil and plasma chamber using the same
NO20034473L (no) Anvendelse av selektive cox-2-inhibitorer ved behandling av urininkontinens
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
SG153647A1 (en) Antineoplastic combinations
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
ECSP034866A (es) Combinaciones antineoplásticas
DE60302152D1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
AR033012A1 (es) Combinaciones antineoplasicas
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
IS2490B (is) Bensóþíasól- og bensoxasól-4,7-díonafleiður og notkun þeirra sem cdc25 fosfatasatálma
DK1589976T3 (da) Anvendelse af en kombination af en aromatase-inhibitor, et progestin og et estrogen til behandling af endometriose
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
IS8390A (is) Notkun á gaboxadóli við meðhöndlun á svefnleysi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application